Middlefield Banc (NASDAQ:MBCN – Get Free Report) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Sunday.
Middlefield Banc Stock Performance
Shares of NASDAQ MBCN opened at $28.71 on Friday. The company has a current ratio of 0.97, a quick ratio of 0.97 and a debt-to-equity ratio of 0.06. The stock has a 50 day simple moving average of $27.96 and a 200-day simple moving average of $24.88. The company has a market cap of $231.69 million, a PE ratio of 16.31 and a beta of 0.69. Middlefield Banc has a 12-month low of $20.61 and a 12-month high of $37.00.
Middlefield Banc (NASDAQ:MBCN – Get Free Report) last released its earnings results on Thursday, October 17th. The bank reported $0.29 earnings per share for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.18). The firm had revenue of $16.82 million during the quarter, compared to analyst estimates of $17.10 million. Middlefield Banc had a return on equity of 6.90% and a net margin of 13.31%. On average, equities research analysts forecast that Middlefield Banc will post 1.79 EPS for the current year.
Institutional Investors Weigh In On Middlefield Banc
Middlefield Banc Company Profile
Middlefield Banc Corp. operates as the bank holding company for The Middlefield Banking Company that provides various commercial banking services to small and medium-sized businesses, professionals, small business owners, and retail customers in northeastern and central Ohio. It offers checking, savings, negotiable order of withdrawal accounts, money market accounts, time certificates of deposit, commercial loans, real estate loans, various consumer loans, safe deposit facilities, and travelers' checks.
Recommended Stories
- Five stocks we like better than Middlefield Banc
- The 3 Best Fintech Stocks to Buy Now
- Intel: Is Now the Time to Be Brave?Â
- What is a support level?
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Top Biotech Stocks: Exploring Innovation Opportunities
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Middlefield Banc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Middlefield Banc and related companies with MarketBeat.com's FREE daily email newsletter.